Omer, Cypb, Pfe And Pwrm Stock Update - Pennytobuck.com
Power3 Medical Products, Inc
Power3 Medical Products, Inc. (OTC:PWRM) reported that, in collaboration with Lourdes R. Bosquez, MD, it has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimers disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer NYSE: PFE), Exelon (Rivastigmine, Novartis NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories NYSE: FRX). These results relate to the genetically distinct groups of Alzheimers disease patients, i.e., those individuals who possess the Alzheimers high-risk gene for Apolipoprotein E4 and those who do not possess the gene.
Pfizer Inc. (NYSE:PFE) reported that the U.S. Food and Drug Administration (FDA) has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A. XYNTHA does not contain von Willebrand factor and, therefore, is not indicated in von Willebrand's disease.
Omeros Corporation (Nasdaq:OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, announced financial results for the three and six months ended June 30, 2010. Total operating expenses for the three and six months ended June 30, 2010 were $8.1 million and $14.9 million, respectively, compared to $6.1 and $11.5 million for the same periods in 2009. The increases in operating expenses were primarily due to higher contract service and consulting costs associated with several of the Company's clinical and preclinical programs as well as increased costs associated with being a public company. In addition, the increases included a one-time payment of $500,000 to Affitech AS in the first quarter of 2010 and a one-time payment of $500,000 to Helion Biotech ApS in the second quarter of 2010 related to the Company's MASP-2 program.
Cypress Bioscience, Inc. (NASDAQ:CYPB), a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system disorders, announced that it has received written notice of consent and effectiveness from the Office of Chief Scientist of the Ministry of Industry, Trade and Labor of the State of Israel (the "OCS") regarding its previously announced in-license agreement for BioLineRx's novel antipsychotic (BL-1020, now CYP-1020), a potential breakthrough treatment for schizophrenia. The agreement, which was amended to reflect input from the OCS, will enable Cypress to build its strategic focus on R&D. There were no material modifications to the agreement and the financial terms of the transaction remain unchanged.
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
by: Bill Pennyman
Mistakes and the Fallen Spoon 3d Projectors And Some Things You Should Know What Are Hedge Funds And Are They Risky? Buy unique and trendy leather briefcases Mandarin Translation and Transcription Selecting Between Traditional and Chimney Fire Pits Back Links - What Are They, Why Do I Need Them and How to Get Them? What Are Back Links and How Do I Get Them? Physical And Spiritual Transformation With Muay Thai Kickboxing Druid Build And Druid Talent Trees Get Him Back Change His Mind In An Instant And Get Him Back Exciting Trends and Patterns of Chimenea Fire Pits Get Him Back Crush All Objections And Have Him Begging You To Take Him Back